Claims
- 1. A therapeutic composition for topical treatment of ocular hypertension or glaucoma comprising therapeutically effective amount of a PGF.sub.2.alpha. isopropyl ester, containing a ring structure, substituted or unsubstituted, on the omega chain, selected from the group consisting of
- 20-phenyl-PGF.sub.2.alpha. isopropyl ester,
- 20-(4-phenylbutyl)-PGF.sub.2.alpha. isopropyl ester,
- 17-(2-thiophene-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,
- 17-(3-thiophene-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,
- 17-methyl-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,
- 17-(4-trifluoromethyl phenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,
- 17-(4-methylphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,
- 17-(2-methylphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,
- 17-(4-fluorophenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,
- 20(methylenephenyl)-PGF.sub.2.alpha. -isopropyl ester,
- 17-napthyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,
- 17-cyclohexyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,
- 17-(4-methoxyphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,
- 17-(3-methoxyphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester,
- 15-cyclohexyl-16,17,18,19,20-pentanor-PGF.sub.2.alpha. isopropyl ester.
- 2. A therapeutic composition of claim 1, comprising 20-phenyl-PGF.sub.2.alpha. isopropyl ester.
- 3. A therapeutic composition of claim 1, comprising 20-(4-phenylbutyl)-PGF.sub.2.alpha. isopropyl ester.
- 4. A therapeutic composition of claim 1, comprising 17-(2-thiophene-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.
- 5. A therapeutic composition of claim 1, comprising 17-(3-thiophene-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.
- 6. A therapeutic composition of claim 1, comprising 17-methyl-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.
- 7. A therapeutic composition of claim 1, comprising 17-(4-trifluoromethyl phenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.
- 8. A therapeutic composition of claim 1, comprising 17-(4-methylphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.
- 9. A therapeutic composition of claim 1, comprising 17-(2-methylphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.
- 10. A therapeutic composition of claim 1, comprising 17-(4-fluorophenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.
- 11. A therapeutic composition of claim 1, comprising 20(methylenephenyl)-PGF.sub.2.alpha. -isopropyl ester.
- 12. A therapeutic composition of claim 1, comprising 17-napthyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.
- 13. A therapeutic composition of claim 1, comprising 17-cyclohexyl-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.
- 14. A therapeutic composition of claim 1, comprising 17-(4-methoxyphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.
- 15. A therapeutic composition of claim 1, comprising 17-(3-methoxyphenyl)-18,19,20-trinor-PGF.sub.2.alpha. -isopropyl ester.
- 16. A therapeutic composition of claim 1, comprising 15-cyclohexy-16,17,18,19,20-pentanor-PGF.sub.2.alpha. isopropyl ester.
- 17. A method of treating ocular hypertension or glaucoma by topical application of the therapeutic composition of claim 1.
Priority Claims (2)
Number |
Date |
Country |
Kind |
8803110 |
Sep 1988 |
SEX |
|
8803855 |
Oct 1988 |
SEX |
|
Parent Case Info
This application is a continuation of Ser. No. 07/740,371, filed Jul. 24, 1991, which is a continuation-in-part of Ser. No. 07/469,442, filed Apr. 10, 1990 both are now abandoned.
US Referenced Citations (14)
Foreign Referenced Citations (1)
Number |
Date |
Country |
573018 |
Feb 1986 |
AUX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
740371 |
Jul 1991 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
469442 |
Apr 1990 |
|